S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Insulet Stock Price, News & Analysis (NASDAQ:PODD)

$194.54
+5.24 (+2.77%)
(As of 12/7/2023 ET)
Compare
Today's Range
$188.88
$194.75
50-Day Range
$127.77
$194.54
52-Week Range
$125.82
$335.91
Volume
860,092 shs
Average Volume
945,218 shs
Market Capitalization
$13.58 billion
P/E Ratio
113.77
Dividend Yield
N/A
Price Target
$258.07

Insulet MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
32.7% Upside
$258.07 Price Target
Short Interest
Bearish
7.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
0.75mentions of Insulet in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$3.29 M Sold Last Quarter
Proj. Earnings Growth
29.84%
From $1.91 to $2.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.11 out of 5 stars

Medical Sector

17th out of 960 stocks

Surgical & Medical Instruments Industry

4th out of 75 stocks


PODD stock logo

About Insulet Stock (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock Price History

PODD Stock News Headlines

Wall Street sees these 2023 losers as 2024 opportunities
Analysts are pointing at undervalued, oversold companies like these three S&P 500 laggards as potential investment opportunities heading into 2024.
Large cap earnings trade ideas for risk-seeking investors (PODD)
Positive earnings surprises (and the magnitude of surprises) are above historical norms as of late - and these three stocks could keep the party going.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Insulet (NASDAQ:PODD) Upgraded to "Overweight" by Morgan Stanley
Morgan Stanley Upgrades Insulet (PODD)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Insulet (PODD) Just Overtook the 50-Day Moving Average
Piper Sandler Reaffirms Their Buy Rating on Insulet (PODD)
The Insulet Corp (PODD) Company: A Short SWOT Analysis
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
2,600
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$258.07
High Stock Price Target
$350.00
Low Stock Price Target
$162.00
Potential Upside/Downside
+32.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
17 Analysts

Profitability

Net Income
$4.60 million
Pretax Margin
8.29%

Debt

Sales & Book Value

Annual Sales
$1.56 billion
Cash Flow
$2.25 per share
Book Value
$6.86 per share

Miscellaneous

Free Float
69,269,000
Market Cap
$13.58 billion
Optionable
Optionable
Beta
0.99

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives















PODD Stock Analysis - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price target for 2024?

17 brokerages have issued 12-month price objectives for Insulet's shares. Their PODD share price targets range from $162.00 to $350.00. On average, they predict the company's stock price to reach $258.07 in the next year. This suggests a possible upside of 32.7% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2023?

Insulet's stock was trading at $294.39 on January 1st, 2023. Since then, PODD shares have decreased by 33.9% and is now trading at $194.54.
View the best growth stocks for 2023 here
.

Are investors shorting Insulet?

Insulet saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 5,370,000 shares, an increase of 65.7% from the October 31st total of 3,240,000 shares. Based on an average daily trading volume, of 1,480,000 shares, the days-to-cover ratio is currently 3.6 days.
View Insulet's Short Interest
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our PODD earnings forecast
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, November, 2nd. The medical instruments supplier reported $0.71 earnings per share for the quarter, beating analysts' consensus estimates of $0.40 by $0.31. The medical instruments supplier had revenue of $432.70 million for the quarter, compared to analyst estimates of $413.82 million. Insulet had a trailing twelve-month return on equity of 23.98% and a net margin of 7.71%.

What guidance has Insulet issued on next quarter's earnings?

Insulet updated its third quarter 2023 earnings guidance on Tuesday, October, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $402.14 million-$412.37 million, compared to the consensus revenue estimate of $414.30 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Clearbridge Investments LLC (2.05%), William Blair Investment Management LLC (1.05%), Primecap Management Co. CA (0.98%), Northern Trust Corp (0.98%), Westfield Capital Management Co. LP (0.91%) and Bank of New York Mellon Corp (0.70%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PODD) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -